{"id":"adx-038","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, ADX-038 aims to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases. This mechanism is thought to be beneficial in conditions where PI3K signaling plays a key role.","oneSentence":"ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:06.355Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of autoimmune diseases"}]},"trialDetails":[{"nctId":"NCT06990269","phase":"PHASE2","title":"Phase 2 Study of ADX-038 in Participants With Geographic Atrophy","status":"RECRUITING","sponsor":"ADARx Pharmaceuticals, Inc.","startDate":"2025-11-10","conditions":"Geographic Atrophy Secondary to Age-related Macular Degeneration","enrollment":240},{"nctId":"NCT06989359","phase":"PHASE2","title":"Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease","status":"RECRUITING","sponsor":"ADARx Pharmaceuticals, Inc.","startDate":"2025-08-28","conditions":"IgAN, C3G, Complement-mediated Kidney Disease","enrollment":45},{"nctId":"NCT05876312","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADARx Pharmaceuticals, Inc.","startDate":"2023-08-07","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["siRNA"],"phase":"phase_2","status":"active","brandName":"ADX-038","genericName":"ADX-038","companyName":"ADARx Pharmaceuticals, Inc.","companyId":"adarx-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Treatment of autoimmune diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}